EyePoint Pharmaceuticals Inc (EYPT) may enjoy gains as insiders got busy in the recent days

EyePoint Pharmaceuticals Inc’s recent filing unveils that its SVP & Chief Commercial Officer Jones David Scott unloaded Company’s shares for reported $5954.0 on Feb 02. In the deal valued at $28.49 per share,209 shares were sold. As a result of this transaction, Jones David Scott now holds 37,962 shares worth roughly $1.09 million.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Then, Paggiarino Dario A. sold 49,325 shares, generating $1,265,539 in total proceeds. Upon selling the shares at $25.66, the Chief Medical Officer now owns 36,505 shares.

Before that, Jones David Scott sold 26,017 shares. EyePoint Pharmaceuticals Inc shares valued at $660,370 were divested by the SVP & Chief Commercial Officer at a price of $25.38 per share. As a result of the transaction, Jones David Scott now holds 37,962 shares, worth roughly $1.09 million.

JP Morgan initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to an Overweight in a research note published on January 22, 2024; the price target was $35.

Price Performance Review of EYPT

On Friday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock fall -1.10% to $28.80. Over the last five days, the stock has gained 0.35%. EyePoint Pharmaceuticals Inc shares have risen nearly 24.62% since the year began. Nevertheless, the stocks have risen 589.00% over the past one year. While a 52-week high of $30.99 was reached on 02/08/24, a 52-week low of $2.21 was recorded on 01/11/24. SMA at 50 days reached $21.91, while 200 days put it at $11.92. A total of 0.55 million shares were traded, compared to the trading of 1.68 million shares in the previous session.

Levels Of Support And Resistance For EYPT Stock

The 24-hour chart illustrates a support level at 28.26, which if violated will result in even more drops to 27.71. On the upside, there is a resistance level at 29.69. A further resistance level may holdings at 30.57. The Relative Strength Index (RSI) on the 14-day chart is 67.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.89, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 28.63%. Stochastics %K at 82.56% indicates the stock is a selling.

How much short interest is there in EyePoint Pharmaceuticals Inc?

A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc stocks on Jan 31, 2024, dropping by -0.19 million shares to a total of 5.14 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2023 was 5.33 million shares. There was a decline of -3.7%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 14.44% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.97.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular